Mechanism of actiondapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (sglt2) which are responsible for at least 90% of the glucose reabsorption in the kidney. blocking this transporter mechanism causes blood glucose to be eliminated through the urine. in clinical trials, dapagliflozin lowered hba1c by 0.6 versus placebo percentage points when added to metformin.dapagliflozin leads to heavy glycosuria